Switch to:
GuruFocus has detected 4 Warning Signs with AbbVie Inc $ABBV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
AbbVie Inc (NYSE:ABBV)
Research & Development
$4,745 Mil (TTM As of Mar. 2017)

This is the expense the company spent on research and development. AbbVie Inc's research and development for the three months ended in Mar. 2017 was $1,135 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2017 was $4,745 Mil.


Definition

This is the expense the company spent on research and development.

AbbVie Inc Research & Development for the trailing twelve months (TTM) ended in Mar. 2017 was 1194 (Jun. 2016 ) + 1186 (Sep. 2016 ) + 1230 (Dec. 2016 ) + 1135 (Mar. 2017 ) = $4,745 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Related Terms

Gross Profit


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

AbbVie Inc Annual Data

Dec09Dec10Dec11Dec12Dec13Dec14Dec15Dec16
Research & Development 001,7072,8083,2913,0663,1933,6494,4354,566

AbbVie Inc Quarterly Data

Dec14Mar15Jun15Sep15Dec15Mar16Jun16Sep16Dec16Mar17
Research & Development 9079381,0041,4181,0759561,1941,1861,2301,135
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

FEEDBACK